<DOC>
	<DOCNO>NCT01842503</DOCNO>
	<brief_summary>Examination effect GET 73 alcohol pharmacokinetics pharmacodynamics ( intoxication sedation ) safety profile alcohol-dependent individuals.To evaluate whether GET 73 , compare placebo , result diminish cue-reactivity response alcohol cue term urge drink cue reactivity session result low quantity alcohol consume alcohol self-administration session .</brief_summary>
	<brief_title>Safety Pharmacodynamic Study GET 73 Alcohol Dependent</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<criteria>male female subject , 21 65 year old ( inclusive ) ; participant must meet criterion current Diagnostic Statistical Manual ( DSMIV ) diagnosis alcohol dependence , support structured clinical interview DSMIV Axis I Disorders Patient Edition ; participant must meet criterion heavy drinking , define average 4 drinks/day woman ≥5 drinks/day men 30day period within 90 day prior screen evaluation ; participant must good health confirm medical history , physical examination , ECG , lab test ; female must postmenopausal least one year surgically sterile . Otherwise , female exclude ( even use kind birth control ) . Proof ( medical record , certification medical doctor ) surgical sterility require . Certification postmenopausal least 1 year postmenopausal level FSH also require study ; participant must willing take oral medication adhere study procedure ; participant must give consent enter study signing inform consent form . individual seek treatment alcohol dependence ; positive urine drug screen baseline positive drug screen follow : opioids , benzodiazepine , cocaine , methamphetamine stimulant . A urine drug screen may repeat must test negative randomization ; individual diagnose current substance dependence , alcohol nicotine ; meet DSMIV Axis I criteria lifetime diagnosis schizophrenia , bipolar disorder , psychoses ; Subjects take psychoactive medication opinion subject primary care physician , discontinue least 14 day prior randomize ; active illness within past 6 month Visit 1 meet DSMIV criterion diagnosis Major Depressive Disorder Anxiety Disorder ; subject history suicide attempt and/or risk suicide exclude , base Structured Clinical Interview Disorders assessment Investigators ' evaluation ; clinically significant medical abnormality ( i.e. , unstable hypertension , clinically significant abnormal ECG , bilirubin &gt; 150 % upper normal limit , alanine aminotransferase aspartate aminotransferase elevation &gt; 300 % upper normal limit , estimate creatinine clearance ≤ 60 dl/min ) ; current use medication prescribe reduce alcohol use e.g . naltrexone , acamprosate , disulfiram topiramate ; concomitant use cytochromeP450 2C19 substrate ; assumption cytochromeP450 2C19 cytochromeP450 3A4 inhibitor inducer 14 day dose ; individual reasonable expectation institutionalize course trial ; participant significant alcohol withdrawal symptom , define Clinical Institute Withdrawal Assessment &gt; 10 ; history seizure ( e.g . epilepsy ) , include alcoholrelated seizure ; history delirium tremens ; subject participate behavioral and/or pharmacological study within past 30 day ; history delirium tremens .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>alcohol dependence</keyword>
	<keyword>cue reactivity</keyword>
	<keyword>alcohol self administration</keyword>
</DOC>